Executive-linked fund sells 150K Royalty Pharma (RPRX) shares under 10b5-1 plan

Rhea-AI Filing Summary

Royalty Pharma plc executive Christopher Hite reported pre-planned insider sales linked to an affiliated entity. On June 23, 2026, SCH Investment Partners LLC, an entity associated with Hite, sold a total of 150,000 Class A Ordinary Shares in open-market transactions at weighted average prices of $54.47 and $54.11 per share.

All transactions were executed under a Rule 10b5-1 trading plan adopted on March 20, 2026, indicating they were scheduled in advance. Following these sales, SCH Investment Partners LLC held 676,991 Class A Ordinary Shares indirectly for Hite, while he also held 70,000 shares directly.

Insights

Insider transactions analyst

Executive-linked entity sold 150,000 Royalty Pharma shares under a pre-planned 10b5-1 program, while retaining a sizable remaining stake.

The filing shows SCH Investment Partners LLC, an entity associated with EVP Christopher Hite, sold 150,000 Class A Ordinary Shares of Royalty Pharma on June 23, 2026. The shares were sold in open-market transactions at weighted average prices around the mid-$50 range.

These sales were made pursuant to a Rule 10b5-1 trading plan adopted on March 20, 2026, which means the trades were pre-scheduled rather than opportunistic. After the transactions, the entity still held 676,991 shares indirectly, and Hite held 70,000 shares directly, so a substantial position remains.

Insider Trade Summary 10b5-1

Net Seller: 150,000 shares ($8,159,277)

Net Sell 3 txns

Insider Hite Christopher

Role EVP & Chairman, Partnering

Sold 150,000 shs ($8.16M)

Type	Security	Shares	Price	Value
Sale	Class A Ordinary Shares	32,408	$54.107	$1.75M
Sale	Class A Ordinary Shares	117,592	$54.4746	$6.41M
holding	Class A Ordinary Shares	--	--	--

Holdings After Transaction: Class A Ordinary Shares — 676,991 shares (Indirect, By SCH Investment Partners LLC); Class A Ordinary Shares — 70,000 shares (Direct, null)

Footnotes (1)

1. All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.39 to $54.38 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.39 to $54.94 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 150,000 shares Tranche 1 weighted average price: $54.4746/share Tranche 2 weighted average price: $54.1070/share +3 more

6 metrics

Shares sold 150,000 shares Total Class A Ordinary Shares sold on June 23, 2026

Tranche 1 weighted average price $54.4746/share First sale block weighted average price

Tranche 2 weighted average price $54.1070/share Second sale block weighted average price

Indirect holdings after sale 676,991 shares SCH Investment Partners LLC position following transactions

Direct holdings after report 70,000 shares Christopher Hite direct Class A Ordinary Share holdings

Rule 10b5-1 plan adoption date March 20, 2026 Date Hite adopted the trading plan governing these sales

Key Terms

Rule 10b5-1 plan, weighted average price, open-market sale, Class A Ordinary Shares, +1 more

5 terms

Rule 10b5-1 plan regulatory

"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average price financial

"The reported price in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Class A Ordinary Shares financial

"security_title": "Class A Ordinary Shares""

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

indirect ownership financial

"direct_or_indirect": "I", "nature_of_ownership": "By SCH Investment Partners LLC""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/25/2026 - 05:12 PM Accepted by SEC EDGAR 06/25/2026 - 05:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hite Christopher

(Last) (First) (Middle)

C/O ROYALTY PHARMA PLC

110 E. 59TH STREET

(Street)

NEW YORK NEW YORK 10022

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chairman, Partnering

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Shares	06/23/2026		S(1)		32,408	D	$54.107(2)	676,991	I	By SCH Investment Partners LLC
Class A Ordinary Shares	06/23/2026		S(1)		117,592	D	$54.4746(3)	559,399	I	By SCH Investment Partners LLC
Class A Ordinary Shares								70,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.39 to $54.38 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.39 to $54.94 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

In addition to the Class A Ordinary Shares disclosed above, family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 866,410 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd ("RPH") exchangeable into 1,238,789 Class A Ordinary Shares. Class E Ordinary Shares of RPH are subject to vesting conditions.

	/s/ Sean Weisberg, as Attorney-in-Fact for Christopher Hite	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Royalty Pharma (RPRX) report for Christopher Hite?

Royalty Pharma reported that an entity associated with EVP Christopher Hite sold 150,000 Class A Ordinary Shares on June 23, 2026. The open-market sales occurred at weighted average prices slightly above $54 per share, and were disclosed on a Form 4 filing.

Who actually sold Royalty Pharma (RPRX) shares in this Form 4 filing?

The sales were made by SCH Investment Partners LLC, an entity associated with executive Christopher Hite. The filing attributes the 150,000-share disposition to this LLC, which holds shares indirectly for Hite rather than through his direct personal account.

How many Royalty Pharma (RPRX) shares were sold and at what prices?

SCH Investment Partners LLC sold 150,000 Class A Ordinary Shares of Royalty Pharma. The filing lists weighted average sale prices of $54.4746 and $54.1070 per share, with individual trades occurring within disclosed price ranges around those levels.

Were the Royalty Pharma (RPRX) insider sales pre-planned under a Rule 10b5-1 plan?

Yes. The footnotes state all reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on March 20, 2026. Such plans schedule trades in advance, so the timing reflects a preset program rather than a spur-of-the-moment decision.

How many Royalty Pharma (RPRX) shares does Christopher Hite still beneficially own after these sales?

After the reported transactions, SCH Investment Partners LLC held 676,991 Class A Ordinary Shares indirectly for Christopher Hite, and he also held 70,000 shares directly. The sales therefore reduced but did not eliminate his overall exposure to Royalty Pharma shares.

What does the Form 4 say about Royalty Pharma (RPRX) share price ranges for these insider sales?

The Form 4 footnotes explain that reported prices are weighted averages. One sale block occurred in multiple trades from $53.39 to $54.38 per share, and another from $54.39 to $54.94 per share, with full trade details available on request.